Summary of Key Points
This article addresses the death of a 6-year-old girl from Shanghai, Xiaomei, who underwent gene therapy and clarifies two common misconceptions: the family's contribution of $860,000 (approximately 6 million RMB) to fund the trial, and the fact that the IIT (Researchers Initiated Trial) model itself is not inherently “heinous.” The real root of the tragedy lies in failures such as the improper handling of funds, the research team's disregard for toxicities observed in animal experiments, and the ethics committee's failure to perform its basic review duties. The article emphasizes that we should not deny the value of patient-funded research or the IIT model in the development of rare diseases due to the mistakes of individual teams; these mechanisms are crucial for advancing new therapies like gene therapy.
Detailed Analysis
1. The Family’s Contribution of 6 Million RMB is Not “Overcharged,” but the Lack of Proper Fund Management is the Major Issue
Many people wonder why clinical trials should not be free and why parents have to pay millions. The article explains that the cost of gene therapy is extremely high:
- High Cost of Vectors: The AAV virus vector used in Xiaomei’s treatment is difficult to produce, and the dosage required is enormous (for example, Zolgensma for SMA requires 110 trillion viral particles per kilogram of body weight).
- High Research Costs: The team had to create mouse models that replicated Xiaomei’s genetic mutation and conduct toxicity tests on macaques. Similar experiments in North America cost $1 million each, and although domestic costs are lower, the $860,000 paid by the family is not exorbitant (most of the funds went to companies involved in virus production and monkey experiments).
The problem lies in the management of these funds: the money was transferred directly to team members rather than through formal university “horizontal funding” agreements (official contracts for corporate or individual-funded research), leaving the family in a passive position. They had no control over potential overspending and were forced to entertain the researchers by dining out, giving them iPhones, and providing茅台, effectively turning the funding party into the supplicating one without any regulatory framework.
2. The IIT Model is Not a “Regulatory Loophole,” but a “Fast Track” for Rare Disease Research
The IIT model involves trials initiated by researchers and does not require approval from drug regulatory agencies; only internal ethics reviews are necessary. Why use this model?
- The Special Nature of Gene Therapy: The same AAV vector can be modified to treat different genetic diseases, but under traditional regulatory processes, each modification would require re-registration, which would significantly delay the development of rare diseases (since the market for these diseases is small and pharmaceutical companies are reluctant to invest).
- International Recognition: Carl June, a pioneer in CAR-T therapy, recommends adopting the Chinese IIT model. Early explorations can be reviewed by institutions, with the FDA intervening only if there are positive results; otherwise, the FDA would be overwhelmed by too many projects (and China needs such flexible mechanisms even more).
- Case Studies: The personalized gene therapy for American infant KJ was also approved through internal institutional reviews, with excellent outcomes.
The IIT model itself is not flawed; the problem lies in its improper implementation in this case—specifically, the team and the review institutions failed to fulfill their responsibilities.
3. The Most Fatal Error: Using a Therapy with Toxic Side Effects in Animals
Before treating Xiaomei, the team conducted toxicity tests on macaques, which showed toxic effects regardless of the dosage. Despite these results, they still decided to use the therapy on her—a nearly unprecedented risk in the industry.
In contrast, the team for infant KJ waited until the monkey experiments confirmed safety before administering the treatment. The Xiaomei team completely ignored these warnings, treating the patient like a lab rat, which was the direct cause of the tragedy.
4. The Ethics Committee Was Completely Ineffective: Approving the Trial Without Reviewing the Results
The ethics committee is supposed to oversee trials, but in this case, it did not even review the results of the monkey experiments. This is like issuing a degree without reviewing a student’s thesis—a fundamental failure in its role.
The article humorously states that even a poorly constituted ethics committee should have caught such obvious issues.
5. Don’t Let Individual Failures Destroy Hope for Rare Disease Patients
The article calls for not dismissing patient-funded research and the IIT model:
- Patient Funding is a Critical Force: Examples include Cai Lei, who funded trials for amyotrophic lateral sclerosis, and foreign parents who founded companies to develop treatments for their children’s diseases (such as Y-mAbs Therapeutics).
- The IIT Model is a Lifesaving Option for Rare Diseases: If the IIT model is banned, many children with rare diseases will lose the chance to try new therapies.
What needs to be done is to hold the responsible research teams and ethics committees accountable, to standardize fund management and review processes, rather than completely abandoning valuable mechanisms for rare disease research.
Conclusion
The tragedy of Xiaomei’s case is not due to the family’s contribution or the IIT model itself, but rather due to human failures in fund management, safety oversight, and inadequate ethical reviews. We must hold those responsible accountable and protect the mechanisms that can bring hope to patients with rare diseases. After all, there are many more “Xiaomeis” out there who await the opportunity for gene therapy.